The CYP2D6 polymorphism in relation to the metabolism of TMG and Sparteineis in the Uighur population

2010 ◽  
Vol 34 (8) ◽  
pp. S31-S31
Author(s):  
ShuChun Li ◽  
GuiPing Wang ◽  
SiFan Xu ◽  
Jian Cui
Keyword(s):  
Cyp2d6 Polymorphism

Gene Frequency of CYP2D6*4 and *10 Variants in Karachi Population

2020 ◽  
Vol 17 ◽  
Author(s):  
Tamkeen Fatima ◽  
Farah Zeb ◽  
A. Dar Farooq
Keyword(s):  
Antipsychotic Drugs ◽  
Screening Program ◽  
Restriction Enzymes ◽  
Normal Subjects ◽  
Control Group ◽  
Poor Metabolizer ◽  
Cyp2d6 Polymorphism ◽  
Wild Allele ◽  
Schizophrenic Patients ◽  
Intermediate Metabolizer

Background: CYP2D6 is to be considered the most pronounced gene in pharmacegenetic field which is involved in metabolizing ~25% of all clinically used neuroleptic drugs and other antidepressants. We designed a study to evaluate differential expression of CYP2D6*4 and CYP2D6*10 variants which are very prevalent in Asian countries and exhibit variation in drug metabolizing ability that affect therapeutic responses. Objective: The purpose of this study is to determine the genotypic frequencies of CYP2D6 *1 (normal metabolizer), *4 (poor metabolizer) and *10 (intermediate metabolizer) variants among schizophrenic subjects and compared with control group from a sub-set of Karachi population. Method: Genomic deoxyribonucleic acid (DNA ) was extracted and amplified with CYP2D6*4 and *10 primers using polymerase chain reaction (PCR) and digested by Bacillus stereothermophilus (BstN1) and Hemophilus parahemolyticus (Hph1) restriction enzymes. The digested bands were identified as wild type or mutants and their genotypic frequencies were estimated statistically by Hardy-Weinberg equation (HWE) and analyzed further under non-parametric Chi-square test. Results: The results mentioned the frequencies of CYP2D6*1 wild allele (57%) which produces functional enzyme in normal subjects but CYP2D6*4 variant (9%) that produces non-functional enzyme and CYP2D6*10 allele (70%) produces altered enzyme with reduced activity that was most prevalent in schizophrenic patients. Conclusion : Genotyping of CYP2D6 alleles among schizophrenic patients indicated prevalence of *4 and *10 variants in Karachi population producing non-functional and reduced functional drugs metabolizing enzymes respectively that increases the incurability rate of schizophrenia. Therefore, CYP2D6 gene screening program should be conducted routinely in clinical practice to help clinicians to prescribing appropriate doses according to patient’s genotype and minimize the sufferings of schizophrenia. Discussion: In last, drug response is a complex phenomenon that is dependent on genetic and environmental factors. CYP2D6 polymorphism may un-cured the schizophrenia due to improper drug metabolism and protein-proteins interaction that may alter the antipsychotic drugs metabolism among patients with variable drug resposes. Gene testing system need to establish for analyzing maximum patient’s genotypes predicted with poor metabolizer, intermediate metabolizer and ultrarapid metabolizer for the adjustment of antipsychotic drugs.

Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels

2016 ◽  
Vol 31 (2) ◽  
pp. 156-162 ◽  
Author(s):  
Natchaya Vanwong ◽  
Nattawat Ngamsamut ◽  
Yaowaluck Hongkaew ◽  
Nopphadol Nuntamool ◽  
Apichaya Puangpetch ◽  
...  
Keyword(s):  
Autism Spectrum Disorder ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Activity Score ◽  
Cyp2d6 Polymorphism ◽  
Cyp2d6 Activity

Modification of the anticancer drug tamoxifen to avoid CYP2D6 polymorphism

2013 ◽  
Vol 91 (9) ◽  
pp. 916-924
Author(s):  
Li Gao ◽  
Xianqiang Sun ◽  
Yaoquan Tu ◽  
Hans Ågren ◽  
Leif A. Eriksson
Keyword(s):  
Dna Adducts ◽  
Formation Enthalpy ◽  
Active Metabolites ◽  
Cyp2d6 Polymorphism ◽  
Cyp2d6 Activity ◽  
Quantum Chemistry Calculations ◽  
Wide Range ◽  
Reaction Energies ◽  
Cyp Isoforms ◽  
Treat Breast Cancer

The prodrug tamoxifen (TAM) is the most widely used drug to treat breast cancer, and is metabolised to the active 4-hydroxy derivatives dominantly by hepatic CYP2D6. However, the application to patients with different polymorphic CYP2D6 has been under debate, because the efficacy of TAM is suspected to be suppressed in patients who have diminished CYP2D6 activity, resulting in inadequate active metabolites. We here propose modified structures, such as 4-methylTAM, which is highly possible to be activated by CYP3A, the most abundant CYP isoforms in the liver, whereby the genetic polymorphism of CYP2D6 is avoided. The diversity of CYP catalyzed metabolic paths for TAM and its derivatives are studied by quantum chemistry calculations on the reaction energies of the initial H atom abstraction steps. The ability of forming DNA adducts is compared through the formation enthalpy of the carbocation intermediate. The results suggest that the modified structures are safe with regard to forming DNA adducts and may be used as prodrugs in a wide range of patients, due to CYP3A, rather than CYP2D6, mediated activation.

CYP2D6 polymorphism in a Mexican American population

2001 ◽  
Vol 70 (6) ◽  
pp. 497-504 ◽  
Author(s):  
R MENDOZA ◽  
Y WAN ◽  
R POLAND ◽  
M SMITH ◽  
Y ZHENG ◽  
...  
Keyword(s):  
Mexican American ◽  
American Population ◽  
Cyp2d6 Polymorphism ◽  
Mexican American Population

No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population

2006 ◽  
Vol 53 (2) ◽  
pp. 162-165 ◽  
Author(s):  
M SCORDO ◽  
M DAHL ◽  
E SPINA ◽  
F CORDICI ◽  
M ARENA
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Italian Population ◽  
Cyp2d6 Polymorphism
Sign in / Sign up

Export Citation Format

Share Document